Concert Pharmaceuticals Inc $ 6.21 0.05 (0.81%)
Volume:
369,372
Avg Vol (1m):
562,147
Market Cap $:
199.80 Mil
Enterprise Value $:
83.86 Mil
PE Ratio:
0.00
PB Ratio:
1.54
Financial Strength | 5/10 |
Current | Vs Industry | Vs History | |
---|---|---|---|
Cash-To-Debt | 8.25 | ||
Equity-to-Asset | 0.82 | ||
Debt-to-Equity | 0.12 | ||
Debt-to-EBITDA | -0.23 | ||
Piotroski F-Score | 4 | ||
Altman Z-Score | 1.75 | ||
Beneish M-Score | 3.31 | ||
WACC vs ROIC |
Profitability Rank | 1/10 |
Current | Vs Industry | Vs History | |
---|---|---|---|
Operating Margin % | -919.35 | ||
Net Margin % | -946.17 | ||
ROE % | -56.72 | ||
ROA % | -46.19 | ||
ROC (Joel Greenblatt) % | -448.49 | ||
3-Year Revenue Growth Rate | -65.5 |
CNCE
Valuation Rank |
Current | Vs Industry | Vs History | |
---|---|---|---|
PB Ratio | 1.54 | ||
PS Ratio | 24.73 | ||
EV-to-EBIT | -1.16 | ||
EV-to-EBITDA | -1.18 | ||
EV-to-Revenue | 10.61 | ||
Current Ratio | 14.02 | ||
Quick Ratio | 14.02 | ||
Days Sales Outstanding | 31.69 |
Dividend & Buy Back |
Current | Vs Industry | Vs History | |
---|---|---|---|
3-Year Average Share Buyback Ratio | -10.5 |
Valuation & Return |
Current | Vs Industry | Vs History | |
---|---|---|---|
Price-to-Tangible-Book | 1.55 | ||
Earnings Yield (Greenblatt) % | -86.78 |